Fewer days of radiation may control brain tumors just as well
NCT ID NCT07167134
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase 3 trial compares two radiation schedules for people with 1 to 5 brain metastases from cancers like melanoma, kidney, or sarcoma. One group gets radiation on days 1, 3, and 5; the other on days 1, 2, and 3. The goal is to see if the shorter schedule controls tumor growth as well or better at 6 months, while reducing treatment burden.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- radiation therapy
- What this could lead to
- If successful, this could offer a more convenient and equally effective radiotherapy schedule for patients with hard-to-treat brain metastases.
- What could go wrong
- This is a phase 3 trial, but it only compares two radiation schedules; it does not test a new drug or cure. The benefit may be modest, and results may not apply to all brain metastasis types.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRAIN METASTASES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
ICANS
Strasbourg, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a 3D camera make brain radiation safer and more precise?
- Pinpoint radiation may spare the brain in lung cancer that spreads
- Spinal fluid DNA test could personalize brain cancer therapy
- Focused radiation doses put to the test for large brain tumors
- Brain scan breakthrough: amino acid PET may solve a tricky diagnosis dilemma
- Spared brain region may shield memory during whole brain radiation